Expand BCTXL Menu
BCTXL MENU

BCTXL Latest Press Releases

-- September 14, 2026 --

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study Globe Newswire 7:30 AM

-- September 8, 2026 --

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center Globe Newswire 7:30 AM

-- August 24, 2026 --

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+ Globe Newswire 7:30 AM

-- August 5, 2026 --

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer Globe Newswire 7:30 AM

-- July 16, 2026 --

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer Globe Newswire 7:30 AM

-- July 15, 2026 --

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT Globe Newswire 7:30 AM

-- July 7, 2026 --

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT Globe Newswire 7:30 AM

-- June 25, 2026 --

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT Globe Newswire 7:30 AM

-- June 2, 2026 --

BriaCell Therapeutics Announces Closing of Offering Globe Newswire 4:05 PM

-- June 1, 2026 --

BriaCell Presents Positive Clinical Data at ASCO 2026 Globe Newswire 7:30 AM

-- May 31, 2026 --

BriaCell Therapeutics Announces Pricing of Offering Globe Newswire 7:59 PM

-- May 26, 2026 --

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer Globe Newswire 7:30 AM

-- May 22, 2026 --

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 Globe Newswire 7:30 AM

-- May 15, 2026 --

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ Globe Newswire 7:30 AM

-- May 14, 2026 --

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer Globe Newswire 7:30 AM

-- May 13, 2026 --

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study Globe Newswire 7:30 AM

-- May 12, 2026 --

BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients Globe Newswire 7:30 AM

-- May 7, 2026 --

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study Globe Newswire 7:30 AM

-- May 6, 2026 --

BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer Globe Newswire 7:30 AM

-- April 27, 2026 --

BriaCell Announces Six Clinical Data Presentations at ASCO 2026 Globe Newswire 7:30 AM

-- April 21, 2026 --

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models Globe Newswire 7:30 AM

-- April 20, 2026 --

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes